NANOLEK announced its cooperation in the area of joint research, development, and manufacturing of vaccines with SK Chemicals, one of the leading biopharmaceutical companies in South Korea.
The agreement was signed at the Eastern Economic Forum in Vladivostok during the meeting held by Russian-Korean Joint Commission on Economic, Scientific and Technical Cooperation.
The agreement was signed by Mikhail Nekrasov, the CEO of NANOLEK, and Jae Yong Ahn, an executive of SK Chemicals.
Within the framework of cooperation the companies plan to conduct joint research, and implement the transfer of technology with the subsequent full-cycle manufacturing of several SK Chemicals vaccines at the NANOLEK plant in the Kirov region.
The first products of this partnership include the vaccines for prevention of rotavirus infection and infection caused by the human papillomavirus. Both vaccines are currently not included in the Russian National Vaccination Schedule, but they are recommended by doctors because of the high prevalence of diseases and potential risk of complications posed by these infections. The vaccines are widely used in Russia and in the world.